Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials

被引：0
|
作者：
You, B.
Gan, H. K.
Pond, G. R.
Chen, E. X.
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Austin Hosp, Melbourne, Vic 3084, Australia
[3] McMaster Univ, Hamilton, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.6031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6031
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology
    Sherry, Alexander D.
    Msaouel, Pavlos
    Kupferman, Gabrielle S.
    Lin, Timothy A.
    Jaoude, Joseph Abi
    Kouzy, Ramez
    Mccaw, Zachary R.
    Ludmir, Ethan B.
    van Zwet, Erik
    JCO PRECISION ONCOLOGY, 2024, 8
  • [42] A stratified adaptive two-stage design with co-primary endpoints for phase II clinical oncology trials
    Cabarrou, Bastien
    Leconte, Eve
    Sfumato, Patrick
    Boher, Jean-Marie
    Filleron, Thomas
    BMC MEDICAL RESEARCH METHODOLOGY, 2022, 22 (01)
  • [43] A stratified adaptive two-stage design with co-primary endpoints for phase II clinical oncology trials
    Bastien Cabarrou
    Eve Leconte
    Patrick Sfumato
    Jean-Marie Boher
    Thomas Filleron
    BMC Medical Research Methodology, 22
  • [44] PRIMARY AND SECONDARY ENDPOINTS USED IN RECENT (2022) ALZHEIMER'S DISEASE (AD) PHASE III CLINICAL TRIALS
    Arjunji, R.
    Massey, J.
    Maru, B.
    Crosland, E.
    Gregory, S.
    Kern, R.
    VALUE IN HEALTH, 2023, 26 (06) : S53 - S54
  • [45] Characterizing discontinuation and withdrawal from phase III oncology clinical trials.
    Malhi, Navraj
    Gresham, Gillian
    Eigl, Bernhard J.
    Grant, Janice
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Associations between prognosis and primary endpoint selection in phase III oncology trials in the United States
    Uemura, Nariaki
    Ono, Shunsuke
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from US Cooperative Oncology Groups
    Schroen, Anneke T.
    Petroni, Gina R.
    Wang, Hongkun
    Thielen, Monika J.
    Gray, Robert
    Benedetti, Jacqueline
    Wang, Xiaofei F.
    Sargent, Daniel J.
    Wickerham, Donald L.
    Cronin, Walter
    Djulbegovic, Benjamin
    Slingluff, Craig L., Jr.
    CLINICAL CANCER RESEARCH, 2012, 18 (01) : 256 - 262
  • [48] The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members
    Maillet, D.
    Blay, J. Y.
    You, B.
    Rachdi, A.
    Gan, H. K.
    Peron, J.
    ANNALS OF ONCOLOGY, 2016, 27 (01) : 192 - 198
  • [49] LOW ADEQUACY BETWEEN SEVERE ADVERSE EVENTS REPORTING IN ONCOLOGY PHASE III TRIALS AND EXPECTATIONS OF THE EORTC MEMBERS
    Maillet, D.
    Blay, J.
    You, B.
    Peron, J.
    ANNALS OF ONCOLOGY, 2014, 25
  • [50] The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology
    Barton, Sarah
    Peckitt, Clare
    Sclafani, Francesco
    Cunningham, David
    Chau, Ian
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (18) : 2732 - 2739
12345